Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo

por Armstrong, J L, Taylor, G A, Thomas, H D, Boddy, A V, Redfern, C P F, Veal, G J
Publicado 2007

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

por Jodrell, D I, Bowman, A, Rye, R, Byrne, B, Boddy, A, Rafi, I, Taylor, G A, Johnston, A, Clendeninn, N J
Publicado 1999

The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ in human leukaemia and colorectal carcinoma cell lines.

por Estlin, E. J., Balmanno, K., Calvert, A. H., Hall, A. G., Lunec, J., Newell, D. R., Pearson, A. D., Taylor, G. A.
Publicado 1997

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer

por Pridgeon, S W, Heer, R, Taylor, G A, Newell, D R, O'Toole, K, Robinson, M, Xu, Y-Z, Karran, P, Boddy, A V
Publicado 2011

A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation

por Estlin, E J, Pinkerton, C R, Lewis, I J, Lashford, L, McDowell, H, Morland, B, Kohler, J, Newell, D R, Boddy, A V, Taylor, G A, Price, L, Ablett, S, Hobson, R, Pitsiladis, M, Brampton, M, Clendeninn, N, Johnston, A, Pearson, A D J
Publicado 2001